evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 50,000 transfections performed and more than 9,000 antibodies expressed and purified for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland) and affordable prices. Transfections are made with serum-free, animal-component free reagents at a monthly capacity of up to 500 liters.
You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.
You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.
Location: Switzerland, Zurich, Schlieren
Employees: 11-50
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | SHS Gesell... | shs-capita... |
Mentions in press and media 8
| Date | Title | Description |
| 14.03.2025 | evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts | 15 years of expertise recombinant antibody expression evitria is celebrating its 15th anniversary with an exciting giveaway that offers an exclusive opportunity to attend the Festival of Biologics in Basel. ZURICH, SWITZERLAND, March 14, 20... |
| 14.05.2024 | Lonza and evitria Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies | evitria AG and Lonza have entered into a license agreement to provide fast access to bYlok® bispecific antibodies. evitria AG has partnered with Lonza to offer rapid access to bYlok® bispecific antibodies for discovery-stage transient expre... |
| 20.02.2024 | Dr. Desmond Schofield new CBO of evitria | As of January 2024, Dr. Desmond Schofield has become new CBO at evitria AG. As of January 2024, Dr. Desmond Schofield has become new Chief Business Officer at evitria AG. ZURICH, SWITZERLAND, February 20, 2024 /EINPresswire.com/ -- evitria ... |
| 03.12.2023 | Antibody Production Companies: Re-shaping Life Sciences Together | Carl Williams, Tech Times 03 December 2023, 08:12 pm (Photo : Michal Jarmoluk from Pixabay) Antibody production companies are essential in dealing with the growing demand for antibodies for life sciences, therapeutic, and diagnostic applica... |
| 10.07.2023 | Diagnostic antibodies – evolution of medical diagnostics | Diagnostic methods in the course of time, along with four approaches in today's diagnostics. BOSTON, MASSACHUSETTS, US, July 10, 2023/EINPresswire.com/ -- Diagnostic antibodies – evolution of medical diagnostics Be it influenza, cancer, or ... |
| 03.05.2023 | Dr. Stefan Schmidt new CEO of evitria | Dr. Stefan Schmidt – new CEO at evitria | © Atlas Antibodies ZURICH, SWITZERLAND, May 3, 2023/EINPresswire.com/ -- Changes are afoot at Swiss company evitria: As of May, Dr. Stefan Schmidt will take over the helm of the company, which speci... |
| 03.08.2021 | Atlas Antibodies acquires biotech service provider evitria | Since its inception in 2010, evitria is a biotech service provider focused on the transient expression of recombinant antibodies in CHO cells. This long-standing and deep focus allows the company to deliver antibodies of exceptional quality... |
| 21.12.2018 | Biotech service provider evitria backed by two new investors |